Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.

doi:10.1111/j.1365-2265.2006.02447.x

Article

Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.

Clinical endocrinology - 1 Feb 2006

Antonelli Alessandro, Rotondi Mario, Fallahi Poupak, Romagnani Paola, Ferrari Silvia Martina, Barani Lucio, Ferrannini Ele, Serio Mario

Abstract excerpt

BACKGROUND: CXCL10 plays an important role in the initial phases of Graves' disease (GD) and autoimmune thyroiditis (AT); however, until now, CXCL10 serum levels (sCXCL10) in patients with GD have never been evaluated in relation to thyroid function and treatment. OBJECTIVE: To evaluate sCXCL10 in GD. DESIGN: Cross-sectional. PATIENTS: One hundred and three GD, 164 AT, 20 nontoxic multinodular goitre (NTMNG), 16...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.

Abstract excerpt

Topics

Related research